Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in fanconi anemia group C

Meenakshi Noll, Raynard L. Bateman, Alan D. D'Andrea, Markus Grompe

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Fanconi anemia (FA) is an autosomal recessive disorder characterized by birth defects, increased incidence of malignancy, progressive bone marrow failure, and cellular hypersensitivity to DNA cross-linking agents. Bone marrow transplantation is therapeutic and therefore FA is a candidate disease for hematopoietic gene therapy. We have previously used mitomycin C (MMC) to achieve in vivo selection of wild-type hematopoietic stem cells (HSC) transplanted into FANCC knockout mice. However, clinical application of MMC in human FA gene therapy is unlikely because of its unknown toxicity profile in human FA patients. In contrast, cyclophosphamide (CPA) and γ-irradiation (IR) are already in use with human FA patients and we therefore tested these regimens for their ability to achieve selection of genetically corrected HSCs in vivo. We found that nonmyeloablative doses of CPA or IR or combinations of CPA + IR were highly efficient at achieving in vivo selection of transplanted wild-type HSC. Furthermore, this nontoxic regimen also selected FANCC-mutant HSC corrected by ex vivo retroviral gene therapy. We suggest those nontoxic doses of CPA and/or IR could also be used to enhance gene therapy in human FA patients.

Original languageEnglish (US)
Pages (from-to)14-23
Number of pages10
JournalMolecular Therapy
Volume3
Issue number1
DOIs
StatePublished - 2001

Fingerprint

Fanconi Anemia
Hematopoietic Stem Cells
Genetic Therapy
Cyclophosphamide
Mitomycin
Bone Marrow Transplantation
Knockout Mice
Hypersensitivity
Bone Marrow
DNA
Incidence
Neoplasms

Keywords

  • γ-irradiation
  • Cyclophosphamide
  • Fanconi anemia
  • Gene therapy
  • Hematopoietic cells
  • Retroviral vector

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in fanconi anemia group C. / Noll, Meenakshi; Bateman, Raynard L.; D'Andrea, Alan D.; Grompe, Markus.

In: Molecular Therapy, Vol. 3, No. 1, 2001, p. 14-23.

Research output: Contribution to journalArticle

@article{f9d70aa7e11a4862bff8ccda11f1c5c0,
title = "Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in fanconi anemia group C",
abstract = "Fanconi anemia (FA) is an autosomal recessive disorder characterized by birth defects, increased incidence of malignancy, progressive bone marrow failure, and cellular hypersensitivity to DNA cross-linking agents. Bone marrow transplantation is therapeutic and therefore FA is a candidate disease for hematopoietic gene therapy. We have previously used mitomycin C (MMC) to achieve in vivo selection of wild-type hematopoietic stem cells (HSC) transplanted into FANCC knockout mice. However, clinical application of MMC in human FA gene therapy is unlikely because of its unknown toxicity profile in human FA patients. In contrast, cyclophosphamide (CPA) and γ-irradiation (IR) are already in use with human FA patients and we therefore tested these regimens for their ability to achieve selection of genetically corrected HSCs in vivo. We found that nonmyeloablative doses of CPA or IR or combinations of CPA + IR were highly efficient at achieving in vivo selection of transplanted wild-type HSC. Furthermore, this nontoxic regimen also selected FANCC-mutant HSC corrected by ex vivo retroviral gene therapy. We suggest those nontoxic doses of CPA and/or IR could also be used to enhance gene therapy in human FA patients.",
keywords = "γ-irradiation, Cyclophosphamide, Fanconi anemia, Gene therapy, Hematopoietic cells, Retroviral vector",
author = "Meenakshi Noll and Bateman, {Raynard L.} and D'Andrea, {Alan D.} and Markus Grompe",
year = "2001",
doi = "10.1006/mthe.2000.0226",
language = "English (US)",
volume = "3",
pages = "14--23",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in fanconi anemia group C

AU - Noll, Meenakshi

AU - Bateman, Raynard L.

AU - D'Andrea, Alan D.

AU - Grompe, Markus

PY - 2001

Y1 - 2001

N2 - Fanconi anemia (FA) is an autosomal recessive disorder characterized by birth defects, increased incidence of malignancy, progressive bone marrow failure, and cellular hypersensitivity to DNA cross-linking agents. Bone marrow transplantation is therapeutic and therefore FA is a candidate disease for hematopoietic gene therapy. We have previously used mitomycin C (MMC) to achieve in vivo selection of wild-type hematopoietic stem cells (HSC) transplanted into FANCC knockout mice. However, clinical application of MMC in human FA gene therapy is unlikely because of its unknown toxicity profile in human FA patients. In contrast, cyclophosphamide (CPA) and γ-irradiation (IR) are already in use with human FA patients and we therefore tested these regimens for their ability to achieve selection of genetically corrected HSCs in vivo. We found that nonmyeloablative doses of CPA or IR or combinations of CPA + IR were highly efficient at achieving in vivo selection of transplanted wild-type HSC. Furthermore, this nontoxic regimen also selected FANCC-mutant HSC corrected by ex vivo retroviral gene therapy. We suggest those nontoxic doses of CPA and/or IR could also be used to enhance gene therapy in human FA patients.

AB - Fanconi anemia (FA) is an autosomal recessive disorder characterized by birth defects, increased incidence of malignancy, progressive bone marrow failure, and cellular hypersensitivity to DNA cross-linking agents. Bone marrow transplantation is therapeutic and therefore FA is a candidate disease for hematopoietic gene therapy. We have previously used mitomycin C (MMC) to achieve in vivo selection of wild-type hematopoietic stem cells (HSC) transplanted into FANCC knockout mice. However, clinical application of MMC in human FA gene therapy is unlikely because of its unknown toxicity profile in human FA patients. In contrast, cyclophosphamide (CPA) and γ-irradiation (IR) are already in use with human FA patients and we therefore tested these regimens for their ability to achieve selection of genetically corrected HSCs in vivo. We found that nonmyeloablative doses of CPA or IR or combinations of CPA + IR were highly efficient at achieving in vivo selection of transplanted wild-type HSC. Furthermore, this nontoxic regimen also selected FANCC-mutant HSC corrected by ex vivo retroviral gene therapy. We suggest those nontoxic doses of CPA and/or IR could also be used to enhance gene therapy in human FA patients.

KW - γ-irradiation

KW - Cyclophosphamide

KW - Fanconi anemia

KW - Gene therapy

KW - Hematopoietic cells

KW - Retroviral vector

UR - http://www.scopus.com/inward/record.url?scp=0034981121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034981121&partnerID=8YFLogxK

U2 - 10.1006/mthe.2000.0226

DO - 10.1006/mthe.2000.0226

M3 - Article

C2 - 11162306

AN - SCOPUS:0034981121

VL - 3

SP - 14

EP - 23

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -